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INTRODUCTION 
Acquired Immunodeficiency Syndrome (AIDS) remains one of the world‟s greatest public 
health challenges with over 25 million mortalities estimated since it was first recognized in 
1981.
[1]
 The highly active antiretroviral therapy (HAART) used in the treatment of AIDS 
utilizes a combination of antiviral drugs with at least two mechanisms of action to effectively 
inhibit the replication cycle of HIV.
[2] 
Due to the persistence and development of drug 
resistance by HIV virus in the infected host cell reservoir and within the tissues, AIDS 
remains an incurable disease. 
HIV, the causative agent of AIDS, is a lentivirus that belongs to the family of Retroviridae.  It 
is genetic information is not encoded as DNA, but as RNA and therefore is reverse-
transcribed into DNA.  
The HIV virus comprises two distinct viruses  HIV-1 and HIV-2, which differ in origin and 
gene sequence. HIV-1 carries the vpu gene whereas HIV-2 carries the vpx gene. These strains 
of HIV share similar molecular structures  they contain a  single-stranded RNA genome and 
both viruses cause AIDS with a similar spectrum of symptoms. Like all viruses, HIV-1 is an 
intracellular parasite and cannot multiply without the host cell.
[3]
 
The structure of  HIV-1 is spherical in the shape. It has two membranes, one outer and one 
inner. The outer membrane of the virus, known as the viral envelope, has a hicosahedral 
shape with a knobby-looking envelope and it consists of a bilayer lipid acquired from the host 
cell, in which are located the envelope glycoproteins (gp) 120 and 41.
[4]
 The inner membrane, 
known as capsid, contains two proteins, p24 and p17, as matrix proteins surrounding the 
nucleocapsid that contains the genetic material. Beneath the envelope there is the viral matrix 
p17, which, aside structural maintenance, enables the DNA copy of the viral genome to be 
transmitted to the host nucleus. Inside there is the p24-capsid. (Fig. 1)  
The RNA genome consists of at least seven structural landmarks (LTR, TAR, RRE, PE, 
SLIP, CRS, and INS), and nine genes (gag, pol, and env, tat, rev, nef, vif, vpr, vpu, and 
sometimes a tenth tev, which is a fusion of tat env and rev), encoding 19 proteins. Three of 
these genes, gag, pol, and env, contain information needed to make the structural proteins for 
new virus particles. The six remaining genes, tat, rev, nef, vif, vpr, and vpu (or vpx in the case 
of HIV-2), are regulatory genes for proteins that control the ability of HIV to infect cells, 
produce new copies of virus (replicate), or cause disease. 
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Fig. 1  structure and life cycle of HIV 
 
The HIV virus, for his life cycle, needs to use cells of human immune system. The life cycle 
starts inside the host cells, in CD4
+
 cells and macrophages.
[5]  
(Fig. 1-2) 
The virus enters in the blood stream of a new host. A protein present  on the surface of the 
virus called gp120 
[6]
, has high affinity for the CD4 receptor found on cells circulating in the 
blood called CD4+ or T helper cells. The virus attaches the host cell, and this binding is 
strengthened further by a co-receptor on the cell surface, called chemokine co-receptor type-5 
(CCR-5) and CXC chemokine receptor type-4 (CXR-4). Once the virion has been bound to 
the host cell surface, its next task is to get inside. This is achieved through the fusion of the 
virus coat and the cell membrane. During the fusion the genetic material of the virus, is 
released into the cell, along with the viral enzymes, reverse transcriptase and integrase. 
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Fig.2     Life Cycle of HIV 
 
Once in the host cell, the Reverse transcriptase reads the viral RNA and builds the 
corresponding DNA strands. The DNA copy is known as a provirus. Viral DNA then moves 
to the cell nucleus, where the cell‟s own genes, also made of DNA, are present. The viral 
enzyme integrase, splices the strands of DNA into the host cell genome and helps the 
integration of virus into the host genome. The proviral DNA can remain as it is for many 
years in a latent state, but when the host cell is in an active form during cell the division, the 
activated RNA polymerase II transcribes the viral DNA into messenger RNA (mRNA) which 
is then translated into viral proteins and polyproteins.  
Together with the RNA  these proteins then migrate  inside  the host cell membrane, where 
they assembly into new virions. Among the viral proteins is the enzyme, protease, which 
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cleaves the polyproteins into smaller, functional proteins, thereby, allowing the new viral 
particles to mature. After the assembly, the newly formed virions bud from the host cell 
surface, entering the bloodstream where they encounter uninfected CD4+ cells and begin 
another cycle .
 [7]     
 
The RT is the enzyme essential for viral replication because is responsible for converting the 
genomic single-stranded RNA of HIV into double-stranded DNA (dsDNA), which 
subsequently becomes integrated into the host genome.  
HIV-1 RT is a multifunctional enzyme that exhibits distinct enzymatic activities. In 
particular,  reverse transcription is carried out using the following three catalytic activities.
 [8] 
 
i) RNA-dependent DNA polymerisation to form an RNA-DNA hybrid  
ii) RNase H degradation of the RNA strand from the RNA-DNA hybrid  
iii) DNA-dependent DNA polymerisation to form a dsDNA.  
 
This enzyme is a dimer of two related chains, a 66-kD subunit (p66) and a 51-kD subunit 
(p51), which is derived from p66 by proteolytic cleavage. The p66 subunit contains the 
polymerase and RNase H active sites as well as the non-nucleoside reverse transcriptase 
inhibitors binding pocket (Fig. 3). The p51 polypeptide corresponds to the polymerase 
subdomain of p66, and comprises the first 440 aminoacids of p66.
[8]
 The subdomains within 
the polymerase domain of each subunit have been named fingers, palm, thumb and 
connection. The additional 120 residues at the carboxyl terminus of p66 comprise the RNase 
H domain. The arrangement of the subdomains in the two subunits is dramatically different. 
In p66, the subdomains are arranged to form a cleft in which the template-primer binding 
cleft and active site residues are buried. There is, therefore, only one functional polymerase 
active site per p66/p51 heterodimer. 
[9]
 
As a result of its crucial role in the life cycle of HIV, RT has been considered to be a good 
drug target 
[10]   
and
 
in the years several inhibitor of this enzyme have been developed. 
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         (a)                                                                              (b) 
Fig. 3        (a) Structure of the HIV-1 reverse transcriptase enzyme adapted from Huang et al. 
                 (b) RNA-directed synthesis followed by DNA-directed synthesis. 
[11] 
 
 
They are classified into two classes :  
a) Nucleoside and nucleotide RT  inhibitors (NRTI)  
b) Non-nucleoside reverse transcriptase inhibitors (NNRTI)  
In the class of  Nucleoside Reverse Transcriptase Inhibitors (NRTI) we can find several drugs 
belonging to the 2',3'-dideoxynucleosides (ddNs), that have been approved by the Food and 
Drug Administration for the treatment of HIV and are commercially available. They include, 
Zidovudine 1 (AZT, Retrovir),
[12]  
Stavudine 2 (d4T, Zerit),
[13] 
 Zalcitabine 3 (ddC, Hivid),
[14] 
Didanosine 4 (ddI, Videx),
[15] 
Lamivudine 5 (3TC, Epivir),
[16]
 Abacavir  
[17]
 and one 
nucleotide analogue, Tenofovir disoproxil fumarate 6 (PMPA, Viread). 
[18]
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Fig. 4 Nucleoside analogues used to treat  AIDS 
 
2',3'-Dideoxynucleosides are the most important class of compounds active against HIV. 
They act as  DNA-chain terminator and competitive inhibitors of viral reverse transcriptase 
(RT).
[19]
 They block DNA elongation is blocked because the chain terminators lack the 3'-OH 
functional group essential for incorporation of additional nucleotides.  
NRTIs are not highly specific and can inhibit normal cellular polymerases, causing serious 
side effects. They must be phosphorylated intracellularly to their 5'-triphosphate form by 
cellular kinases before to act as chain terminators in the RNA-directed DNA polymerisation 
reaction catalysed by HIV-1 RT. In their 5'-triphosphated form these dideoxynucleosides 
compete with the natural substrate of RT showing selective anti-HIV activity comparable to 
that of Zidovudine 1 (AZT) in vitro. Stavudine 2 (d4T) is less toxic and less inhibitory to 
mitochondrial DNA Nucleotide analogues binding at the dNTP-binding site, adjacent to the 3' 
terminus of the primer strand that is located in the palm subdomain of the p66 subunit.  
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NRTIs are subjected to drug resistance and in particular two biochemical mechanism of 
NRTI drug resistance are known. The first mechanism is mediated by mutations that allows 
the RT enzyme to discriminate NRTI during DNA synthesis, therefore preventing their 
addition to the growing DNA chain. The second mechanism is mediated by nucleotide 
excision mechanism (NEM) that increase the rate of hydrolytic removal of the chain 
terminator of NRTI and continue DNA synthesis.  In the second mechanism the oxygen anion 
of a nucleoside diphosphate or triphosphate is used as a pyrophosphate nucleophile to attack 
and cleave the phosphate bond of the primer, producing an unblocked primer and a 
dinucleoside or tetraphosphate containing the dideoxynucleoside monophosphate from the 
primer terminus linked through its phosphate group to the distal phosphate of the free 
nucleoside di or triphosphate . 
[20]
 
Due to drug resistance, a considerable effort has be made two find new antiviral molecules. 
In 1987 when the first NRTI  1 (AZT) was approved for the treatment of HIV infection, the 
understanding of the replication cycle of the HIV virus was limited and the molecular targets 
that are known today to be central to HIV replication had not been identified yet.
[21] 
A broad 
screening of the Janssen compound library in the early nineties led to the discovery of  
TIBOand α-APAas anti-HIV agents. This was followed by systematic leading optimization, 
which yield the first generation of NNRTIs such as Tivirapine, a TIBO derivative, and 
Loviride,  an α-APA derivative. These compounds were effective against wild-type HIV-1 
but had lower potency when tested against common NNRTI-resistant mutants. Chemical 
modifications were introduced in these TIBO and α-APA derivatives, resulting in a 
systematic structure-based molecular modeling study which played a key role in 
understanding the three dimensional structure-activity relationships in these two chemically 
distinct series.  
The disclosure of TIBO compounds inspired the search for more potent and selective RT 
inhibitors.
  
To date, more than 30 structurally diffrent NNRTIs have been identified. They 
include HEPT derivatives 7, Thiocarboxanilide derivatives 8,
[22] 
quinoxaline derivatives 9, 
[23]
  
and  PETT  derivatives 10. 
[24] 
 (Fig.5)  
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 Fig. 5  Chemical structures of some selected NNRTI inhibitors 
 
The number of compounds within the NNRTIs  rapidly increased and by the end of 1998, the 
following three compounds had been approved for clinical use by the FDA Nevirapine 11, 
[25] 
 
Delavirdine 12 
[26]
 and Efavirenz 13. 
[27]
 (Fig.6) 
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Fig. 6  NNRTIs approved for the treatment of AIDS 
Unfortunately also this class of inhibitors was vulnerable to HIV‟s high mutation rate, which 
resulted in a rapid selection of resistant strains. This tempered the initial enthusiasm and even 
led some groups to abandon NNRTI research altogether. 
[28]
  
By early 2000, structural activity studies around the α-APAs led to produce 
imidazoylthiourea (ITU) derivatives.  An effort to improve the metabolic stability of the ITUs 
led to the serendipitous discovery of DATA compounds. These compounds have a triazine 
ring that replaced the unstable thiourea moiety of ITU (Fig. 7). Molecular modeling of DATA 
compounds suggested that replacing the central triazine ring with a pyrimidine ring it would 
be improved the activity. This structural modification led to the discovery of etravirine, a 
diarylpyrimidine (DAPY) derivative, that is highly potent and effective against wild-type and 
drug-resistant HIV-1 mutants. 
[29]
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 Fig. 7  Chemical structures of second-generation NNRTIs. 
 
NNRTIs bind at a largely non-conserved site. The NNRTI binding site („pocket‟) is located in 
the p66 domain  about 10Å away from the substrate binding site. The residues in this pocket 
are mainly of hydrophobic nature with substantial aromatic character. The pocket region can 
also contains a few hydrophilic residues and backbone atoms that may form hydrogen bonds 
to non-nucleoside compounds, which all include hydrogen-bond donor and acceptor groups. 
The NNRTIs block the HIV-1 reaction through interaction with an allosterically located, non-
substrate binding site. 
[30]
 The NNRTI binding in this pocket causes a repositioning of the 
three-stranded β-sheet in the p66 subunit, which contains the catalytic aspartic acid residues 
100, 185 and 186. This inhibits HIV-1 RT by locking the active catalytic site into an inactive 
conformation, reminiscent of the conformation observed in the inactive p51 subunit. 
[31]
 
Steady state kinetic studies carried out have revealed that NNRTI  do not prevent the binding 
of nucleotide triphosphate substrates to the enzyme, but they block the chemical step of NRTI 
incorporation. 
[32]
 
When bound into their pocket, the first-generation NNRTIs maintain a „butterfly-like‟ shape. 
They roughly overlay each other in the binding pocket and appear to function as electron 
donors to aromatic side-chain residues lining the pocket. 
[33]
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In crystal structures of unliganded HIV-1 RT the non-nucleoside inhibitor binding site 
(NNIBS) does not exist. During the process of  binding significant conformational changes 
occur in the orientation of the side chains of Tyr181 and Tyr188 leading to the formation of 
the hydrophobic pocket accommodating the inhibitor. It is evident from a comparison of the 
various RT structures that the NNIBS has a very flexible structure, and that this flexibility 
apparently allows the enzyme to accommodate structurally diverse inhibitors with different 
shapes and sizes. In fact, side-chain residues adapt themselves to each bound inhibitor in a 
highly specific manner, closing the surface of the drug to make tight van der Waals 
interactions. 
[34]
 
Structural studies around N-(2-phenylethyl)-N'-(2-thiazolyl)thiourea (PETT) led to the 
discovery of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2(5-bromopyridyl)]-thiourea 17 (Fig.8) 
which was designed to optimize occupancy of the binding pocket. 
[35]
 Docking experiments 
of HI-236 revealed that the 2-methoxy group was situated beneath the ethyl linker and fits 
favourably into a cavity of the binding pocket, providing additional interactions with the 
protein residues. 
[36]
 
                            
             
N
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OMe
Br
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H
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17  
Fig. 8      1-(5-bromopyridine-2-yl)-3-[dimethoxyphenyl)ethyl]thiourea (HI-236) 
Structure-activity study of ring A showed that the methoxy group substitution is more 
favourable on the meta (to the alkyl side chain) position, compared to the para position. 
Fluorine substitution is favourable on the ortho and meta positions, whereas chlorine was 
only favourable at the ortho position. Similarly, a hydrophobic group is more desirable than 
polar group or hydrophilic group at the para position. 
[37] 
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NNRTIs have been notorious for rapidly triggering the emergence of drug-resistant HIV 
virus.  Resistance usually emerges when an NNRTI is administered as a monotherapy. 
NNRTI resistance mutations arise rapidly causing changes in the binding of NNRTI to RT. 
The most common mutations are Lys103 with Asn and Tyr181 with Cys.
[38]
 The mutations 
cause a loss of aromaticity, by reducing favourable interactions, and indirectly affects NNRTI 
potency by stabilizing the closed form of the non-nucleoside inhibitor binding pocket 
(NNIBP) through the formation of a hydrogen bond between the Asn103 side-chain amide 
and the  oxygen of the phenoxy group, reducing the rate of inhibitor entry.
[39]
 The Leu100 
mutation cause steric interference between the β-branching isoleucine and a bound NNRTI. 
The  mutation causes resistance through steric hindrance of the methyl side chain and the  
bound inhibitor. 
[40]
  
Mutations associated with resistance to nevirapine involve residues which have van der 
Waals interaction with the inhibitor. Mutations of these residues lead to the weakening of the 
inhibitor binding to RT. 
[41]
 The most common resistance mutation observed for nevirapine in 
vivo  is prevented from emerging by co-administration of AZT. The mutually antagonistic 
effects of different resistance mutations and the hypersensitivity that is seen under some 
conditions, argues in favour of the combined use of NNRTIs with NRTIs and different 
NNRTIs with another one. 
[42]
 
Because of resistance, combination of drug therapy is often used to exploit the synergistic 
and additive activities of individual drugs. “Highly active anti-retroviral therapy” (HAART), 
is a treatment regime that commonly combines the use of two NRTIs and one NNRTI or 
protease inhibitor.
[43]
 Combinations of NRTI and NNRTIs have been found to decrease viral 
load, increase CD4 count, decrease mortality and delay disease progression to AIDS. 
[44]
  
 
Giuseppe Campiani reported a series of  quinoxalinylethylpyridylthiourea as potent Non-
Nucleoside HIV-1 Reverse Transcriptase (RT) Inhibitors. (Fig. 9) 
[45],[46]  
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Fig. 9  
The derivatives reported showed excellent biological activity as potent Non-Nucleoside  
HIV-1  Reverse Transcriptase Inhibitors showed in table 1.  
 
18 a
18 b
18 c
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18 g
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7,9-diF   CH       N         C       CH
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H CH C N N
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7,8-diMe
R            A         X        Y         Z W T
0.029
0.04
0.022
0.02
0.009
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0.015
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0.22
0.03
0.4
Compound IC50(M)
 
Table 1. Inhibition of HIV-1 Wild type RT Enzymes. 
   
All compounds showed IC50 value at nanomolar concentration and in particular compound  
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18d, 18e and 18g showed higher IC50  than marketed Efavirenz. 
Based on encouraging results shown by quinoxalinylethylpyridylthiourea derivatives it was 
decided to substitute the five term ring with an isoindol ring in order to verify their antiviral 
activity, considering the experience gained from my research group on isoindolquinoxaline 
compounds. 
 
Quinoxalines and structurally related quinoxalinones represents an important class of 
biologically and medicinally important compounds. A large number of synthetic quinoxalines 
showed  antineoplastic, antibacterial, antiviral, antifungal activity. 
[47],[48]
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Fig.10   Common heterocyclic quinoxalines and quinoxalines like compounds with biological             
activity. 
 
In the last years our research group was interested in the synthesis of quinoxalines and 
Isoindolequinoxalines derivatives biologically active as anticancer compounds. 
[49]
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Fig.11 General chemical structer of isoindole intermediates. 
Isoindolo[1,2-a]quinoxalines compounds were synthesized starting from isoindole 
intermediates with diffrent substituents for both stabilize and functionalize the isoindole 
moiety. The synthesized compounds had an electron-withdrawing substituent at C-1, which 
stabilize the isoindole structure, high electron density at the position 3 and also a phenyl 
substituted moiety on the nitrogen bearing a important amine group showed in fig 11. 
                                   
                                     
N
N
R
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R3H
X
23
X = O
X = NH
        
                         
a  R= R1 =R2 = R3 =H
b  R= R1 = R2 =H, R3 =Me
c  R =R1 =R3 =H,= R2 =OMe
d  R=R3 =H,R1 =R2 =Me
e  R =R3 =H, R1 =R2 =Cl
Fig.12  Isoindole[2,1-a]quinoxalines
                             
All five isoindolequinoxalines synthesised were tested at National Cancer Institute (NCI, 
Bethesda) and showing high anticancer activity. They were firstly tested against three cancer 
cell lines (MCF7-breast, NCI-H460-nonsmall cell lung and SF-268-CNS) at one dose 
concentration (10
-4 
M). 
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All Isoindole[2,1-a]quinoxalines compounds (ISQ) 23a-e were selected for the biological 
evaluation on the full (NCI) panel of about 60 human cancer cell lines and determined 
parameters of GI50,TGI and LC50. All of them showed antineoplastic activity against all 
human cancer cell line tested. The biological data reported showed the most active compound 
is the 3 methoxy-compound 23c with pGI50 of 7.32. After that to increase the water solubility 
of these compounds a new series of ISQ with a NH group instead a carbonyl one, were 
synthesized. These latter compounds showed comparable activity with the previous one. In 
order to study how different substituents can influence the biological activity, more 
compounds  prepared using different kind of substitution on the aromatic rings and changing 
substituent‟s position both in benzene fused ring and in the indole portion. The newly 
synthesised derivatives showed more potent activity against cancer than previously reported 
isoindolequinoxalines.  
 
These synthesised derivatives 24 a-g were also submitted to the National Cancer Institute of 
Bethesda (NCI) and tested in a full panel of about 60 different tumour cell lines.  
They showed antitumor activity against the total number of cell lines investigated with pGI50 
mean values from 5.91 to 7.87  showed in table 2. 
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NSC Compd. No. of the  
Cell Lines 
Investigated 
No. of cell lines giving positive PGI50 
 Range MG_MID 
 747520 24a 56 56 >8.00 – 5.42 7.57 
 747526 24b 56 56 >8.00 – 4.81 7.75 
 747521 24c 54 53 7.86 – 4.37 6.95 
 747523 24d 54 54 >8.00 – 5.92 7.87 
 747522 24e 56 56 >8.00 – 5.98 7.70 
 747524 24f 46 46 7.14 – 5.70 6.38 
 477525 24g 58 58 7.14 - 5.64 5.91 
   
  Table 2 
 
 
 
The most active compound was compound 24d, whose pGI50 mean value was 7.87.  
It is interesting to note that the two derivatives 24f and 24g, in which the methoxy group 
position was changed, are less active than 24d they showing pGI50 of 6.38 and 5.91 
respectively. (Table 2) 
In fig.13 is reported the mean graph of the most active compound 24d (NSC 747523) whose 
GI50 value reached nanomolar concentration on 89% of the cell lines and 20% of the cell lines 
at TGI. 
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Fig. 13 
20 
 
The compound 24d was selected for in vivo screening 
Fig. 14 
In vivo test performed on Ovcar-3 tumor showed that at the dose of 15 mg/kg 24d induced a 
significant reduction of the tumor although accompanied by a decrease of the body weight which was 
however recovered. (Fig. 14) 
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Considering the good biological activity of  ISQ and considering the commercially available 
starting material used to obtain compounds 23, it was proposed to synthesize  compounds of 
type 25 and 26 with the insertion of the side chains present in the Campiani‟s compounds on 
derivatives  23.  For the synthesis of new derivatives isoindoloqunoxalinethylpyridylthiourea 
the route involves the preparation of intermediate 5H-isoindol[2,1-a]quinoxalin-6-
ylideneamine, obtained by following previously reported reaction process. 
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                                                   SYNTHESIS 
 
We started the synthetic route from the 5H-isoindolo[2,1-a]quinoxalin-6-ylideneamine  
intermediates 30a-e.  
They were synthesized from the commercially available o-phtaldehyde 27 and the substituted 
o-phenylenediamines 28a-e. They were reacted in the presence of sodium hydrogen sulphite 
and potassium cyanide in water to give 1-cyano-2-(2‟aminophenyl) isoindoles 29a-e in 60-
80% yield. 
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KCN
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CN
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Reflux/NaHCO3
27 28 a-e
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H
 
                                                        
 
                                                          a R=R1=H, R2=H 
                                                                      b R=R2=H, R1=OMe 
                                                                      c R=R2=H, R1=Me 
                                                                      d R= H, R1=R2=Cl 
                                                                      e R=H, R1=R2=Me 
 
Compounds 29a-e were then dissolved in acetic acid and refluxed  for 30 min. The resulting 
reaction mixture was neutralized with sodium hydrogen carbonate at 0°C obtaining 5H-
isoindolo[2,1-a]quinoxalin-6-ylideneamine  intermediates 30a-e in 60-90% yield. 
23 
 
 
Once synthesized the 5H-isoindolo[2,1-a]quinoxalin-6-ylideneamine  intermediates 30a-e 
were functionalized using compound 35 synthesized from reaction between 2-chloroethanol 
31 and sodium azide 32 in DMF under reflux for 64 hours. The 2-azidoethanol 33 obtained 
was then treated with p-toluenesulfonyl chloride 34 in the presence of pyridine at room 
temperature for 6 hours to obtain the desired compound 35 in 60% yield. 
 
 
 
Cl
OH NaN3
DMF,Reflux.
64,hrs.
N3
OH
CH3S
O
O
Cl
Pyridine,r.t.
6 hrs.
CH3S
O
O
O
N3
31 32
33
34
35
 
 
 
Isoindolquinoxalines 30a-e were reacted with tosylethyl azide 35 in the presence K2CO3 in 
DMF at 90
°
C giving a mixture of ethylazide substituted quinoxaline 36a-e and 37a-e. The 
two ethylazide isomers were separated by column chromatography to give 36a-e and 37a-e in 
30-50 % yield and 25-30 % yield. 
24 
 
                                
R2
H
NH
R
R1N
N
N
NNH
R2
R1
R
N
NN
N3
R2
R1
R
N3
36a-e
37a-e
SH
SH
TEA
N
NNH
R2
R1
R
NH2
TEA
N
NN
NH2
R2
R1
R
39a-e
SH
SH
40 a-e
CH3S
O
O
O
N3
35
K2CO3,DMF,
Reflux,12,hrs
38
38
H
H
30 a-e
   
 
 
The substituted azide 5-(2-azido-ethyl)-5H-isoindolo[2,1-a]quinoxalin-6-ylideneamine 
intermediates 36a-e and (2-azido-ethyl)-isoindolo[2,1-a]quinoxalin-6-yl-amine 37a-e were 
subjected to reduction using propane-1,3-dithol 38 and triethylamine at room temperature for 
a R=R1=H, R2=H 
b R=R2=H, R1=OMe 
c R=R2=H, R1=Me 
d R= H, R1=R2=Cl 
e R=H, R1=R2=Me 
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24 hours under argon atmosphere to give the corresponding substituted amines 39a-e and 
40a-e in 60-80% yield. 
The substituted amino intermediates 39a-e and 40a-e were functionalized with 
bromopyridylthiourea 43. It was synthesized from 2-amino-5-bromo-pyridine 41 and 1,1‟-
Thiocarbonyldiimidazole 42 in chloroform at room temperature under nitrogen in 74% yield. 
   
N
Br
NH2
N N
S
N
N
CHCl3
r.t.,N2,12 hrs
N
Br
N C S
41 42 43
 
Once synthesised compound 43 was reacted with amino intermediates 39a-e and 40a-e in 
DMF at 100°C to give the desired compounds 44a-d (20-30%) and 45a-d (20-35%).          
                                          
N
NHN
NH2
R
R1
R2
N
Br
NCS
DMF,100°C
N
NHN
N
R
R1
R2
16 hrs.
N
N
H
H
S
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43
39a-d
44a-d
+
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In case of compounds  39e and 40e the reaction was unsuccessful. 
N
NHN
NH2
R
R1
R2
N
Br
NCS
DMF,Heat
16 hrs.
43
39 e
No Reaction
N
NN
H2N
R
R1
R2
N
Br
NCS
DMF,Heat
16 hrs.
43
No Reaction
40 e
H
+
+
 
 
I tried to synthesize compound 44e and 45e using different methods and reaction conditions 
but synthesis was not possible.  
 
 
 
27 
 
                                                       INTRODUCTION 
 
Indole (2,3-benzopyrrole, ketole, 1-benzazole C8H7N) is an aromatic heterocyclic organic 
compound that has a bicyclic structure consisting of a six-membered benzene ring fused to a 
five-membered pyrrole ring. The participation of the nitrogen ione pair  in the aromatic ring 
means that indole is not a base and it does not behave like a simple amine. The name indole  
come from  the words “indigo” and “oleum” since indole was first isolated by treatment of 
the indigo dye with oleum. Indole and many of its derivatives are the most important 
structural components in many naturally occurring compounds, having a wide variety of 
pharmacological and biological properties. Moreover substituted indoles are very important 
intermediates for the synthesis of classes of biologically important compounds. Likewise, 
pyrrole derivatives are present in compounds such as bile pigments, vitamin B12, haemin, 
chlorophyll, and related natural products. In addition several pyrrole derivatives are important 
intermediates for the synthesis of drugs, pigments and pharmaceuticals. Certain indole 
derivatives were important dyestuffs until the end of the 19
th
 century. In the 1930, interest in 
indole increased, when it became known that the indole nucleus is present in many important 
alkaloids, as well as in tryptophan and auxins, and it remains an active area of research 
today.
[50] 
The indole moiety is one of the most attractive scaffolds with a wide range of 
biological and pharmacological activities. This chemically  important nucleus is frequently 
found in therapeutic agents  as well as in natural products. 
For example indole-3-yl-glyoxylamide derivatives 46 are potent biological active agents, this 
led to the synthesis of a large number of structural compounds containing indole-2-carboxylic 
moiety as an invariable ingredient. The diversity and rapid access to small and highly 
functionalized organic molecules makes this approach of  current interest in the  drug 
discovery process. 
[51] 
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         Fig. 15   General structure of  indole-3-yl-glyoxylamide. 
 
Therapeutic importance of indole glyoxylamide derivatives showed high affinity against the 
benzodiazepine binding site receptors. Indole-3-yl-glyoxylamide derivatives showed wide 
spectrum of pharmacological activities as anticancer,
 
anti-HIV, antiviral,
[52]
 antimicrobial,
[53]
 
cardiovascular.
[54]
    
It was described 
[55]
 the discovery of indole-3-glyoxamide 47 (fig.16) derivative as the first 
small molecule inhibitor of the gp120-CD4 interaction (HIV-1 attachment inhibition) that 
demonstrate potent antiviral activity in cell culture. 
[56]
 
 
                                    
N
N
O
O
H
N
O
F
  
                                                 47 
 Fig. 16  Indole-3-glyoxamide.  
 
Heterocyclic compounds bearing Indole-3-yl-glyoxylamide ring system are endowed with 
variety of biological activities. 
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Replacing one of the carbon atoms at positions 4 to 7 in the indole moiety with a nitrogen 
atom gives the azaindoles 
[57]
 which are known as indole bioisosteres 
[58]
 and, although some 
examples exist in the nature, most of they are synthetic products. Indoles and azaindoles 
belong to the fused [5,6]-membered ring systems. They are often classified as purinomimetics 
or purine isosteres, and exhibit a wide range of biological activities and pharmacological 
properties.
[59]
 These rings are part of synthetic products of naturally occurring alkaloids, such 
as 7-aza-rebeccamycin and 5-aza-ellipticine. Their biological activities are based mostly on 
their affinity toward DNA, but also as topoisomerase inhibitors and as potential kinase 
inhibitors.
[60]
 
 
N N
N
N
N
NH2
NH2
Variolin B
N
N
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N N
CH3
Neocryptolepine
48 49 50
 
 
Fig. 17 Common chemical structure of natural products containing azaindol moiety. 
 
The interest in azaindole compounds increased for their medicinal importance and 
applications in material synthesis and coordination chemistry, and some azaindole are 
contained in compounds existing in nature, like variolins,
[61]
 grossularines 
[62]
 and 
neocryptolepine.
[63] 
 
Azaindole ring systems have attracted considerable interest from the chemistry as they 
represent promising building blocks with potential applications in the ﬁeld of 
pharmaceuticals, natural product synthesis and also diverse key synthetic intermediates.  
For example a new class of therapeutics for treatment of AIDS as integrase inhibitors is 
known, by recent approval, to be azaindole compounds as raltegravir 51 and in encouraging 
phase II clinical trial elvitegravir 52  and S/GSK1349572 53. 
[64]
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Also Tanis et.al. recently reported the discovery of azaindol N-methyl hydroxamic acids 54 
as potent HIV-1 integrase inhibitors. 
[65]
 
 
 
                                             
NN
N
O
OH
CH3
XF
54   X=H
       X=F     
 
 
These azaindol N-methyl hydroxamic acids showed potent antiviral activity as integrase 
inhibitors.  
Hui Xu reported the synthesis of some N-arylindoles with HIV-1 integrase inhibition activity. 
[66]
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They synthesised substituted arylindoles 55a-h as showed in fig.18 showed potent activity 
against HIV-1 as integrase inhibirors. All compounds were tested in vitro for their HIV-1 
integrase activity (EC50) and cytotoxicity (CC50) in cell based assay against HIV-1integrase 
replication in acutely infected C8166 cells. In addition , the therapeutic index (TI) was also 
calculated as showed in table 3 and 3‟-azido-3‟-deoxythymidine (AZT) was used as control.       
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N
N N
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Fig. 18 Structures of different N-arylindoles . 
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Compounds CC50(µg/ml) EC50(µg/ml) TI 
55 a 91.44 35.82 2.55 
55 b 191.9 7.88 24.61 
55 c >200 82.28 >2.61 
55 d 5.40 2.93 1.90 
55 e 99.61 11.24 9.48 
55 f >200 37.76 >6.63 
55 g 157.14 19.22 8.26 
55 h 14.41 12.09 1.28 
AZT 1288.24 0.007 184034.28 
 
Table. 3  Anti HIV-1 integrase inhibition activity of some N-arylindoles . 
 
Considering the promising biological activity of these compound . Our research group was 
interested to insert a nitrobenzene group to the 6-azaindole moiety. 
  
 
 
 
 
 
 
 
 
 
 
  
33 
 
                                                              SYNTHESIS 
 
For the synthesis of desired product we started from commercially available 4-methyl-
pyridines 56a-c that were treated with iron powder in acetic acid to give substituted 4-methyl-
pyridin-3-ylamine 57a-c, these latter amine intermediates were reacted with 2-fluoro-1-
nitrobenzene 58 in the presence of sodium hydride in dimethylformamide to give the 
substituted nitro-phenyl-amine products  59a-c in 70-80% yield. 
 
N R
R1
CH3
56 a-c
N
CH3
R1
R
R2
R2
Iron Powder,Acetic Acid
Reflux ,8 hrs
57 a-c
N
N
NO2
R
CH3 H
NO2
FNaH,
DMF,r.t
   6hrs.
59 a-c
R1
58
a R=Cl, R1=NO2, R2=H
b R=Cl, R1=H, R2=NO2
c R=H,  R1=NO2, R2=H
a R=Cl, R1=H
b R=H, R1=Cl
c R=H, R1=H
a R=Cl, R1=NH2, R2=H
b R=Cl, R1=H, R2=NH2
c R=H, R1=NH2, R2=H
 
Compound 59a-c were reacted with diethyl oxalate 60 in the presence of potassium tert-
butoxide in ethanol and diethyl ether. The resulting reaction mixture was refluxed for 8 hours 
and it was  concentrated, dissolved in water and acidified with acetic acid to reach pH 4. The 
precipitate was collected by filtration and purified to obtain compounds 61 a-c  in 50-52%  
yield. 
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R
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a R=Cl, R1=H
b R=H, R1=Cl,
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Compounds 61a-c were dissolved in acetic acid and refluxed for 2 hours then cooled to room 
temperature, dissolved in water and extracted with ethyl acetate. After concentration under 
reduced pressure the desired products 62a-c were obtained in 60-65% yield. 
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EXPERIMENTAL DATA 
 
Synthesis of substituted 1-cyano-2-(2’-aminophenyl)isoindoles 29a-e . 
To a solution of sodium hydrogen sulfite (1g, 0.015mol) in water (38 ml) phthalaldehyde 28 
(2g, 0.015mol) was added. The mixture was stirred until the solid was dissolved, and the 
appropriate 1,2-phenylenediamine 27a-e (0.015mol) was added. The reaction was heated in a 
steam bath for 30 min. Then KCN (3.39g, 0.052 mol) in water (8.0 ml) was added, and the 
mixture was heated for an additional 90 min. The solid formed upon cooling was filtered and 
purified by column chromatography. In the case of derivative 29-d, the 1,2-phenylenediamine 
27-d was first dissolved in DMF (15 ml) and then added to the reaction mixture. 
 
General procedure synthesis of substituted 5H-Isoindolo[2,1-a]quinoxalin-6-
ylideneamine  30a-e 
 
1-Cyano-2-(2‟-aminophenyl) isoindoles 29a-e (3 mmol) were dissolved in acetic acid (10 ml) 
and refluxed for 30min. The reaction mixture was poured into ice water (150 ml).The 
resulting precipitate was collected by filtration and recrystallized from ethanol. 
 
5H-Isoindolo[2,1-a]quinoxalin-6-ylideneamine 
M.p. 255-265°C, yield-99 %, IR : 3390, 3203 (NH), 1685 (C=NH) cm
-1
. 
1
H-NMR (DMSO-d6): 7,75 (1H, dt, J=7.0, 1.6 Hz, Ar-H), 7.78-7.91 (2H, m, 2xAr-H), 7.93 
(1H, s, Ar-H), 7.96 (1H, t, J=7.8 Hz, Ar-H), 8.00 (1H, t, J=7.8 Hz, Ar-H), 8.27 (1H, dd, 
J=7.0, 1.6 Hz, Ar-H), 8.34 (1H, d, J=7.8 Hz, Ar-H), 8.84 (1H, d, J=7.8 Hz, Ar-H), 12.35 (1H, 
bs, NH). 
13
C-NMR (DMSO-d6): 124.1 (d), 127.0 (d), 127.5 (d), 127.8 (d), 127.9 (d), 128.9 (d), 130.9 
(d), 131.4 (d), 133.1 (s), 133.4 (d), 135.3 (s), 138.9 (s), 141.0 (s), 143.9 (s), 161.7 (s). 
 
3-Methoxy-5H-isoindolo[2,1-a]quinoxalin-6-ylideneamine  
M.p. 293-294°C, yield-75 %, IR : 3363, 3280 (NH), 1635 (C=NH) cm
-1
. 
1
H-NMR (DMSO-d6): 3.84 (3H, s, CH3), 7.04 (1H, s, Ar-H), 7.05 (1H, d, J=9.8 Hz, Ar-H), 
7.40 (1H, t, J=7.8Hz, Ar-H), 7.51 (1H, t, J=7.8 Hz, Ar-H), 7.95 (1H, d, J=7.8 Hz, Ar-H), 8.36 
(1H, d, J=9.8, Hz, Ar-H), 8.51 (1H, d, J=7.8 Hz, Ar-H), 9.18 (1H, s, Ar-H), 13.50 (1H, bs, 
NH). 
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13
C-NMR (DMSO-d6): 55.7 (q),101.5 (d), 104.6 (s), 112.7 (d), 115.7 (d), 116.2 (s), 118.2 
(d), 119.1 (d), 120.9 (d), 124.3 (d), 124.4 (s), 126.2 (d), 128.5 (s), 147.1 (s), 158.9 (s),  
 
4-Methyl-5H-isoindolo[2,1-a]quinoxalin-6-ylideneamine 
M.p. 338-339°C, yield-98 %, IR : 3360, 3284 (NH), 1632 (C=NH) cm
-1
. 
1
H-NMR (DMSO-d6): 2.62 (3H, s, CH3), 7.32-7.40 (2H, m, Ar-H), 7.45 (1H, t, J=6.8 Hz, 
Ar-H), 7.51 (1H, t, J=8.8 Hz, Ar-H), 7.96 (1H, d, J=8.8 Hz, Ar-H), 8.27 (1H,d, J=6.8 Hz, Ar-
H), 8.47 (1H, d, J=8.8 Hz,Ar-H), 9.24 (1H, s, Ar-H), 12.53 (1H, bs, NH). 
13
C-NMR (DMSO-d6): 17.8 (q), 104.8 (s), 114.8 (d), 117.3 (d), 119.2 (d), 121.5 (d), 122.3 
(s), 125.0 (d),125.1 (s), 125.2 (d), 125.3 (s), 127.1 (d), 127.3(sx2), 130.0 (d), 147.0 (s). 
 
2,3-Dichloro-5H-isoindolo[2,1-a]quinoxalin-6-ylideneamine 
M.p. 340-343°C, yield-87 %, IR : 3350, 3302 (NH), 1645 (C=NH) cm
-1
. 
1
H-NMR (DMSO-d6): 7.43 (1H, t, J=7.8 Hz, Ar-H), 7.54 (1H, t, J=7.8 Hz, Ar-H), 7.86 (1H, 
s, Ar-H), 7.95 (1H, d, J=7.8 Hz, Ar-H), 8.52 (1H, d, J=7.8 Hz, Ar-H), 8.85 (1H, s, Ar-H), 
9.32 (1H, s, Ar-H), 12.46 (1H, bs, NH). 
13
C-NMR (DMSO-d6): 105.1 (s), 117.1 (d), 118.7 (d), 119.2 (d), 119.4 (d), 121.1 (d), 122.0 
(s), 124.7 (s), 124.8 (d), 126.5 (s), 126.9 (s), 127.0 (d),127.2 (s), 130.3 (s), 147.0 (s). 
 
 2,3-Dimethyl-5H-isoindolo[2,1-a]quinoxalin-6-ylideneamine 
M.p. 370-371°C, yield-96 %, IR : 3365, 3286 (NH), 1631 (C=NH) cm
-1
. 
 
1
H-NMR (DMSO-d6): 2.30 (3H, s, CH3), 2.35 (3H, s, CH3), 7.31 (1H, s, Ar-H), 7.46 (1H, t, 
J=7.8 Hz, Ar-H), 7.57 (1H, t, J=7.8 Hz, Ar-H), 8.00 (1H, d, J=7.8 Hz, Ar-H), 8.09 (1H,s, Ar-
H), 8.41 (1H, d, J=7.8 Hz, Ar-H), 9.02 (1H, s, Ar-H), 13.14 (1H, bs, NH). 
13
C-NMR (DMSO-d6): 19.5 (q), 19.6 (q), 116.7 (d), 117.4 (d), 118.7 (s), 119.1 (d), 119.6 
(d), 121.0 (s), 122.0 (d), 125.3 (s), 125.4 (d), 125.8 (s), 127.6 (d), 127.9 (d), 135.9 (s), 139.0 
(s), 147.2 (s). 
 
Synthesis of 2-Azido-ethanol 33 
 2-Chloroethanol 31 (10g ,124.2 mmol) was dissolved in DMF (35 ml) and sodium azide 32 
(10.6g, 173.8 mmol) was added. The reaction mixture was heated at 80°C  for 64 hrs. Then it 
was  allowed to cool to room temperature and extracted with ethyl acetate .The organic layer 
was washed with water and dried over sodium sulfate. The solvent was evaporated under 
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reduced pressure and the crude was purified by chromatography using dichloromethane and 
ethyl acetate as eluent (9:1. DCM:EA) 
Oil, Yield 74 %, IR: 3386 (OH), 2105 (N3) cm
-1
. 
1
H-NMR (CDCl3):
 
3.43 (2H, t, J=5 Hz, CH2), 3.77 (2H, t, J=5Hz, CH2), 5.00 (1H, t, 
J=5.1,Hz, OH) 
13
C-NMR (CDCl3): 53.4 (t), 61.3 (t). 
 
Synthesis of toluene-4-sulfonic acid 2-azido-ethyl ester 35  
The 2-azido-ethanol 33 (5g, 57.47 mmol) was dissolved in pyridine (35ml) and 
p-toluenesulfonyl chloride 34 (16.37g, 86.20 mmol) was added to the reaction mixture at 
0°C.The reactiom mixture warmed to room temperature  and stirred for 3 hrs. It was diluted 
with diethyl ether (100 ml), aqueous hydrochloric acid (2 N, 20 ml) was added slowly and 
reaction stirred vigorously for 10 min. The aqueous layer was separated and extracted with 
diethyl ether, the organic layer was dried over sodium sulphate and concentrated under 
reduced pressure. The crude product was purified by coloumn chromatography using 
dichloromethane and ethyl acetate as eluent (9:1 DCM:EA) .  
Oil, Yield 80 %,  IR:   2111 (N3), 1365 (SO2) cm
-1 
1
H-NMR (CDCl3):
 
 2.44 (3H, s, CH3), 3.56 (2H, t, J=4.7 Hz, CH2), 4.16 (2H, t, J=4.7 Hz, 
CH2), 7.51 (2H, d, J=8 Hz, 2xAr-H ), 7.82 (2H, d, J=8 Hz, 2xAr-H ). 
13
C-NMR (CDCl3): 21.0 (q), 48.9 (t), 69.2 (t), 127.6 (d x 2), 130.2 (d x 2), 145.1 (s), 
147.0 (s). 
 
Synthesis of substituted 5-(2-Azido-ethyl)-5H-isoindolo[2,1-a]quinoxalin-6- 
aylideneamine 36-e and (2-Azido-ethyl)-isoindolo[2,1-a]quinoxalin-6-yl-amine  37a-e . 
A solution of 5H-Isoindolo[2,1-a]quinoxalin-6-ylideneamine 30a-e (0.5g, 2.13 mmol) in 
DMF (7 ml) was stirred at room temperature for 10 min. Then potassium carbonate ( 0.73g, 
5.34mmol) was added to the reaction mixture and stirred for 2 hours at room temperature. 
Then tosylethyl azide 35 (1.5g, 6.41 mmol) was added and the reaction mixture was heated 
at 90
°
C for 12 hours. The reaction mixture was quenched with water and extracted with ethyl 
acetate. The solvent was evaporated under reduced pressure and the crude was purified by 
chromatography using dichloromethane and ethyl acetate as eluent (8:2 DCM:EA) 
 
5-(2-Azido-ethyl)-5H-isoindolo[2,1-a]quinoxalin-6- aylideneamine 36a 
M.p. 165
°
C, yield 30%, IR:  3688 (NH), 2256 (N3), 1718 (C=NH) cm
-1 
. 
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1
H-NMR (CDCl3): 3.83 (2H, t, J=6 Hz, CH2), 5.05 (2H, t, J=6 Hz,CH2), 7.80-7.90 (3H, m, 
3xAr-H), 7.98 (1H, dd, J=1.5, 8 Hz, Ar-H), 8.05 (1H, dd , J=1.3, 7.2 Hz, Ar-H), 8.2-8.31 (2H, 
m, 2xAr-H), 8.35 (1H, dd, J=1.5 Hz, Ar-H), 9.26 (1H, dd, J=1.8 Hz, Ar-H). 
13
C-NMR (CDCl3): 50.2 (t), 66.5 (t), 122.6 (s), 124.7 (d), 125.3(d), 129.1 (d), 129.2 (d), 
129.3 (s), 130.5 (d), 130.8 (d), 132.5 (d), 134.9 (s), 137.6 (s), 142.3 (s), 143.2 (s), 140.2 (s), 
143.4(s). 
 
5-(2-Azido-ethyl)-3-methoxy-5H-isoindolo[2,1-a]quinoxalin-6-aylideneamine 36b 
M.p.189
°
C, Yield 34%,  IR: 3021(NH), 2204 (N3), 1694 (C=NH)  cm
-1
. 
1
H-NMR (CDCl3): 3.83 (2H, t, J=6 Hz, CH2), 4.02 (3H, s, OCH3), 5.08 (2H, t, J=6 Hz, CH2), 
7.46-7.55 (2H, m, 2xAr-H), 7.80-8.02 (3H, m, 3xAr-H), 8.18 (1H, d, J=10 Hz, Ar-H), 8.41 
(1H, d, J=8.4 Hz, Ar-H), 9.19 (1H, d, J=8.4 Hz, Ar-H) 
13
C-NMR (CDCl3): 29.7 (t), 50.2 (t), 55.8 (q), 99.9 (d), 105.5 (d), 122.0 (s), 123.7 (d), 124.1 
(d), 124.4 (s), 125.2 (d), 130.0 (d), 130.3 (d), 132.3 (d), 135.0 (s), 135.3 (s), 137.8 (s), 145.0 
(s), 161.4 (s). 
 
5-(2-Azido-ethyl)-3-methyl-5H-isoindolo[2,1-a]quinoxalin-6- aylideneamine 36c  
M.p. 161
°
C, Yield 30%,  IR: 3442 (NH), 2256 (N3), 1729 (C=NH) cm
-1
 
1
H-NMR (CDCl3): 2.98 (3H, s, CH3), 3.82 (2H, t, J=5 Hz, CH2), 5.08 (2H, t, J=5Hz, CH2), 
7.67-8.04 (5H, m,  5xAr-H), 8.16 (1H, dd, J=2.4, 7.5 Hz, Ar-H), 8.42 (1H, tt, J=0.7, 9.3 Hz, 
Ar-H), 9.25 (1H, dt, J=0.7, 9.3 Hz, Ar-H). 
13
C-NMR (CDCl3): 17.9 (q), 50.2 (t), 66.3 (t), 122.6 (d), 124.6 (d), 125.3 (d), 127.2 (d), 
129.0 (d), 130.2 (d), 130.6 (d), 132.4 (d), 135.0 (s), 137.0 (s), 137.3 (s) 141.4 (s), 142.6 (s), 
143.8 (s), 146.6 (s). 
 
5-(2-Azido-ethyl)-2,3-dichloro-5H-isoindolo[2,1-a]quinoxalin-6- aylideneamine 36d 
M.p. 169
°
C, Yield 40%,  IR: 3409 (NH), 2257 (N3), 1722 (C=NH) cm
-1 
1
H-NMR (CDCl3): 3.83 (2H, t, J=5Hz, CH2), 5.03 (2H, t, J=5Hz, CH2), 7.83-8.06 (3H, m, 3x 
Ar-H), 8.36-8.43 (3H, m, 3xAr-H), 9.18 (1H, d, J=8.6, 2Hz, Ar-H). 
13
C-NMR (CDCl3): 50.1 (t), 66.7 (t), 122.8 (d), 124.9 (d), 125.5 (d), 129.4 (d), 129.6 (d), 
131.4 (d), 132.8 (d), 133.9 (s), 134.4 (s), 135.1 (s), 138.5 (s), 139.7 (s), 141.7 (s), 148.0 (s), 
163.5 (s). 
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5-(2-Azido-ethyl)-2,3-dimethyl-5H-isoindolo[2,1-a]quinoxalin-6- aylideneamine 36e 
M.p. 183
°
C, Yield 38%,  IR:  3396 (NH), 2257 (N3), 1614 (C=NH) cm
-1  
1
H-NMR (CDCl3): 2.57 (6H, s, 2xCH3), 3.82 (2H, t, J=5 Hz, CH2), 5.02 (2H, t, J=5 Hz, 
CH2), 7.80-8.05 (5H, m, 5xAr-H), 8.40 (1H, dd, J=0.7, 7.9 Hz, Ar-H), 9.21 (1H, dd, J=0.7, 
7.9 Hz, Ar-H). 
13
C-NMR (CDCl3): 20.4 (q), 20.7 (q), 50.2 (t), 66.3 (t), 122.3 (d), 124.4 (d), 125.2(d), 127.9 
(d), 128.0 (d), 130.3 (d), 132.2 (d), 135.2 (s), 136.5 (s), 140.1 (s), 140.4 (s), 141.5 (s),142.2 
(s), 147.0 (s) 162.1 (s). 
 
6-(2-Azido-ethoxy)-isoindolo[2,1-a]quinoxaline 6-yl-amine  37a 
M.p. 156
°
C, Yield 37%,  IR: 3428 (NH), 2257 (N3) cm
-1 
. 
1
H-NMR (CDCl3): 3.77 (2H, t, J=6 Hz, CH2), 4.80 (2H, t, J=6 Hz, CH2), 7.45 (1H, d, J=8 
Hz, Ar-H), 7.60 (1H, d, J=8 Hz, Ar-H), 7.71-8.08 (4H, m, 4xAr-H), 8.20 (1H, d, J=6 Hz, Ar-
H), 8.41 (1H, d, J=8 Hz, Ar-H), 8.91 (1H, d, J=8 Hz, Ar-H). 
13
C-NMR (CDCl3): 39.5 (t), 48.1 (t), 127.1 (d), 127.5 (d), 127.6 (d), 128.0 (d), 128.6 (d), 
128.7 (d), 129.7 (d), 131.1 (d), 131.6 (d), 131.7 (s), 132.3 (s), 133.7 (s), 138.5 (s), 140.2 (s), 
143.3 (s). 
 
6-(2-Azido-ethoxy)-3-methoxy-isoindolo[2,1-a]quinoxaline 6-yl-amine 37b 
M.p. 180
°
C, Yield 32 %,  IR: 3480 (NH), 2256 (N3) cm
-1 
 
1
H-NMR (CDCl3): 3.78 (2H, t, J=6Hz, CH2), 3.99 (3H, s, OCH3), 4.79 (2H, t, J=6Hz, CH2), 
7.40-7.50 (2H, m, 2xAr-H), 7.82-8.08 (4H, m, 4xAr-H), 8.39 (1H, d, J=0.9 Hz, Ar-H), 8.84 
(1H, d, J=7.1 Hz, Ar-H). 
13
C-NMR (CDCl3): 29.7 (t), 50.2 (t), 55.8 (q), 99.9 (d), 105.5 (d), 122.0 (s), 123.7 (d), 124.1 
(d), 124.4 (s), 125.2 (d), 130.0 (d), 130.3 (d), 132.3 (d), 135.0 (s), 135.3 (s), 137.8 (s), 145.0 
(s), 161.4 (s). 
 
6-(2-Azido-ethoxy)-3-methyl-isoindolo[2,1-a]quinoxaline 6-yl-amine 37c 
M.p. 147
°
C , Yield 33 %, IR  3391 (NH), 2257 (N3) cm
-1     
1
H-NMR (CDCl3): 2.80 (3H, s, CH3), 3.80 (2H, t, J=6.5 Hz, CH2), 4.95 (2H, t, J=6.5 Hz, 
CH2), 7.58-8.06 (6H, m, 6xAr-H), 8.53 (1H, dd, J=1.7, 8 Hz, Ar-H), 8.97 (1H, dd, J=1.7, 8 
Hz, Ar-H). 
13
C-NMR (CDCl3): 17.3 (q), 39.7 (t), 48.4 (t), 124.4 (d), 127.0 (d), 127.3 (d), 128.2 (d), 
128.6 (d), 129.6 (s), 130.8 (d), 131.1 (d), 132.9 (s), 133.3 (d), 136.1 (s), 139.5 (s), 139.9 (s). 
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141.4 (s), 143.8 (s). 
 
6-(2-Azido-ethoxy)-2,3-dichloro-isoindolo[2,1-a]quinoxaline 6-yl-amine 37d 
M.p. 152
°
C , Yield 38 %,  IR: 3427 (NH), 2256 (N3) cm
-1     
1
H-NMR (CDCl3): 3.77 (2H, t, J=6 Hz, CH2), 4.92 (2H, t, J=6 Hz, CH2), 7.83-7.93 (3H, m, 
3xAr-H), 8.21 (1H, s, Ar-H), 8.33 (1H, s, Ar-H), 8.52 (1H, d, J=7.7 Hz, Ar-H), 8.95 (1H, d, 
J=7.7 Hz, Ar-H). 
13
C-NMR (CDCl3): 39.9 (t), 47.6 (t), 124.7 (d), 125.1 (s), 127.4 (d), 128.5 (d), 128.8 (d), 
129.6 (d), 131.9 (d), 132.4 (s), 133.6 (s), 133.7 (d), 135.5 (s), 139.5 (s), 139.6 (s), 158.6 (s), 
161.9 (s). 
 
6-(2-Azido-ethoxy)-2,3-dimethyl-isoindolo[2,1-a]quinoxaline 6-yl-amine 37e 
M.p. 168
°
C , Yield 30 %,  IR:  3475 (NH), 2257 (N3) cm
-1 
1
H-NMR (CDCl3): 2.53 (6H, s, 2xCH3), 3.77 (2H, t, J=6.4 Hz, CH2), 4.95 (2H, t, J=6.4 Hz, 
CH2), 7.67 (1H, td, J=4.0,2.0 Hz, Ar-H), 7.76-7.95 (4H, m, 4xAr-H), 8.53 (1H, d, J=8Hz, Ar-
H), 8.95 (1H, d, J=8Hz, Ar-H) 
13
C-NMR (CDCl3): 20.2 (q), 20.5 (q), 39.7 (t), 48.7 (t), 124.2 (d), 127.0 (d), 127.1 (d), 127.8 
(s), 128.1 (d), 128.2 (d), 128.5 (d), 129.6 (s), 130.7 (d), 133.2 (s), 133.3(d),134.4 (s), 138.4 
(s), 138.9 (s), 139.7 (s), 141.8 (s). 
 
Synthesis of substituted 5-(2-Amino-ethyl)-6-imino-5,6-dihydro-isoindolo[2,1-
a]quinoxaline 39a-e and N
1
-Isoindolo[2,1-a]quinoxalin-6-yl-ethane-1,2-diamine  40a-e 
The azide intermediates 39a-e and 40a-e (0.1g, 0.3mmol) were dissolved in anhydrous 
methanol and transferred to the reaction flask under argon atmosphere containing  
1-3,propane dithiol. ( 0.1g, 0.94 mmol) and triehlylamine (1.3g, 0.94 mmol) was added. 
Reaction mixture was  stirred for  24 hrs . The solvent was evaporated under reduced pressure 
and the crude was purified by chromatography using dichloromethane and ethyl acetate as 
eluent (8:2. DCM:EA). 
 
5-(2-Amino-ethyl)-6-imino-5,6-dihydro-isoindolo[2,1-a]quinoxaline 39a 
M.p. 194
°
C , Yield 72 %, IR: 3679, 3556 (NH2), 3393 (NH), 1719 (C=NH) cm
-1 
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1
H-NMR (CDCl3): 3.83 (2H, t, J=5Hz, CH2), 5.03 (2H, t, J=5Hz, CH2), 7.80-8.05 (5H, m, 
5xAr-H), 8.27-8.35 (2H, m, 2xAr-H), 8.42 (1H, dd, J=0.8,9.2Hz, Ar-H), 9.25 (1H, dd, J=0.8, 
9.2 Hz, Ar-H). 
13
C-NMR (CDCl3): 39.5 (t), 48.1 (t), 127.1 (d), 127.5 (d), 127.6 (d), 128.0 (d), 128.6 (d), 
128.7 (d), 129.7 (d), 131.1 (d), 131.6 (d), 131.7 (s), 132.3 (s), 133.7 (s), 138.5 (s), 140.2 (s), 
143.3 (s). 
 
5-(2-Amino-ethyl)-6-imino-3-methoxy-5,6-dihydro-isoindolo[2,1-a]quinoxaline 39b 
M.p. 198.8
°
C , Yield 62 %, IR: 3584, 3437 (NH2), 3319 (NH), 1721 (C=NH) cm
-1 
1
H-NMR (CDCl3): 3.77 (2H, t, J=6.1Hz, CH2), 3.98 (3H, s, OCH3), 4.77 (2H, t, J=6.1 Hz, 
CH2), 7.35-8.09 (5H, m, 5xAr-H), 8.37 (1H, d, J=7.2 Hz, Ar-H), 8.79 (1H, d, J=7.2, Hz, Ar-
H), 8.59 (1H, d, J=8Hz, Ar-H). 
13
C-NMR (CDCl3): 18.8 (q), 40.1 (t), 48.0 (t), 105.5 (d), 121.6 (d), 123.5 (d), 126.4 (s), 
127.9 (d), 128.6 (s), 129.9 (d), 130.8 (d), 131.6 (d),132.5 (s), 132.6 (s), 133.5 (d), 134.5 (s), 
142.1 (s), 143.5 (s). 
 
5-(2-Amino-ethyl)-6-imino-3-methyl-5,6-dihydro-isoindolo[2,1-a]quinoxaline 39c 
M.p. 189
°
C , Yield  64%,  IR: 3604, 3501 (NH2), 3407 (NH), 1713 (C=NH) cm
-1
 
1
H-NMR (CDCl3): 2.82 (3H, s, CH3), 3.82 (2H, t, J=5Hz, CH2), 5.07 (2H, t, J=5Hz, CH2),  
7.60-8.19 (5H, m, 5xAr-H), 8.16 (1H, dd, J=2.3,7.4 Hz, Ar-H), 8.40 (1H, d, J=8Hz, Ar-H), 
9.25 (1H, dd, J=0.8,8 Hz, Ar-H). 
 13
C-NMR (CDCl3): 18.0  (q), 50.3 (t), 66.4 (t), 122.6 (d), 124.6 (d), 125.3 (d), 127.2 (d), 
129.0 (d), 130.2 (d), 130.6 (d), 132.4 (d), 135.0 (s), 137.0 (s), 137.3 (s), 141.4 (s), 142.6 (s), 
146.6 (s), 162.6 (s). 
 
5-(2-Amino-ethyl)-2,3-dichloro-6-imino-5,6-dihydro-isoindolo[2,1-a]quinoxaline 39d 
M.p. 182
°
C , Yield 78%,  IR: 3679, 3558 (NH2), 3393 (NH), 1719 (C=NH) cm
-1
 
1
H-NMR (CDCl3): 3.83 (2H, t, J=5Hz, CH2), 5.03 (2H, t, J=5Hz, CH2), 7.83-8.06 (3H, m,  
3xAr-H), 8.36-8.43 (3H, m, 3xAr-H), 9.18 (1H, d, J=8.6, 2Hz, Ar-H). 
13
C-NMR (CDCl3): 50.1(t), 66.7 (t), 122.8 (d), 124.9 (d), 125.5 (d), 129.4 (d), 131.4 (d), 
132.8 (d), 133.7 (d), 133.9 (s), 134.4 (s), 135.1 (s), 138.5 (s), 139.7 (s), 141.7 (s), 148.0 (s), 
163.5 (s). 
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5-(2-Amino-ethyl)-6-imino-2,3-dimethyl-5,6-dihydro-isoindolo[2,1-a]quinoxaline 39e 
M.p.186
°
C , Yield  60 %,  IR: 3558, 3392 (NH2), 3219 (NH), 1725 (C=NH) cm
-1
 
1
H-NMR(CDCl3): 2.57 (6H, s, 2xCH3), 3.82 (2H, t, J=5Hz, CH2), 5.03 (2H, t, J=5Hz, CH2), 
7.81-8.07 (5H, m, 5xAr-H), 8,41 (1H, d, J=8Hz, Ar-H), 9.22 (1H, d, J=8Hz, Ar-H). 
13
C-NMR (CDCl3): 20.2 (q), 20.5 (q), 39.7 (t), 48.7 (t), 124.2 (d), 127.0 (d), 127.1 (d), 127.8 
(s), 128.1 (d), 128.5 (d), 129.6 (s), 130.7 (d), 133.2 (s), 133.3 (d), 134.4 (s), 138.4 (s), 138.9 
(s), 139.7 (s), 141.8 (s). 
 
N
1
-Isoindolo[2,1-a]quinoxalin-6-yl-ethane-1,2-diamine 40a 
M.p. 177
°
C , Yield 58%,  IR: 3688, 3557 (NH2), 3370 (NH) cm
-1
 
1
H-NMR (CDCl3): 3.76 (2H, t, J=6.2 Hz, CH2), 4.78 (2H, t, J=6.2 Hz, CH2), 7.77-8.07 (6H, 
m, 6xAr-H), 8.19 (1H, td, J=1.7, 2Hz, Ar-H), 8.39 (1H, dd, J=1,7.8 Hz, Ar-H) 
8.86 (1H, dd, J=1, 7.8 Hz, Ar-H) 
13
C-NMR (CDCl3): 39.8 (t), 48.8 (t), 124.5 (d), 127.3 (s), 127.8 (d), 128.0 (d), 128.4 (d), 
128.6 (d), 129.2 (d), 129.6 (d), 129.7 (s), 130.9 (d), 131.3 (d), 132.9 (s), 140.9 (s), 142.6 (s), 
143.5 (s). 
 
N
1
-(3-Methoxy-isoindolo[2,1-a]quinoxalin-6-yl)-ethane-1,2-diamine 40b 
M.p.192.4
°
C , Yield 60 %,  IR: 3566, 3446 (NH2), 3398 (NH) cm
-1
 
1
H-NMR(CDCl3): 3.76 (2H, t, J=6.2 Hz, CH2), 3.97 (3H, s, OCH3), 4.75 (2H, t, J=6.2 Hz, 
CH2), 7.32 (1H, d, J=2.6 Hz, Ar-H), 7.42 (1H, dd, J=2.7, 9 Hz, Ar-H), 7.79-8.06 (4H, m, 
4xAr-H), 8.35 (1H, dd, J=1, 7.8 Hz, Ar-H), 8.77 (1H, dd, J=1,7.8 Hz, Ar-H). 
13
C-NMR (CDCl3): 18.8 (q), 39.4 (t), 48.0 (t), 121.6 (d), 123.5 (d), 126.4 (s), 127.9 (d),  
128.6 (d), 129.9 (d), 130.8 (d),131.6 (d), 132.5 (s), 132.6 (s),133.6 (d), 134.5 (s), 142.2 (s), 
143.5 (s), 161.4 (s). 
 
N
1
-(3-Methyl-isoindolo[2,1-a]quinoxalin-6-yl)-ethane-1,2-diamine 40c 
M.p. 168
°
C , Yield 64%,  IR: 3689, 3567 (NH2), 3372 (NH) cm
-1
 
1
H-NMR(CDCl3): 2.73 (3H, s, CH3), 3.78 (2H, t, J=6.3 Hz, CH2), 4.78 (2H, t, J=6.3 Hz, 
CH2), 7.62-8.05 (6H, m,6x Ar-H), 8.39 (1H, dd, J=1,7.7 Hz, Ar-H), 8.84 (1H, dd, J=1,7.7Hz, 
Ar-H). 
13
C-NMR(CDCl3): 16.7 (q), 39.6 (t), 47.7 (t), 123.9 (d), 126.5 (d), 127.5 (d), 128.0 (d), 
128.2.(d), 129.7 (d), 130.7 (d), 131.5 (d), 131.6 (s), 132.2 (s), 133.6 (s),134.9 (s), 135.4 (s) 
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138.5 (s), 139.1 (s). 
 
N
1
-(2,3-Dichloro-isoindolo[2,1-a]quinoxalin-6-yl)-ethane-1,2-diamine 40d 
M.p. 164
°
C , Yield 60 %,  IR: 3671 ,3584 (NH2), 3419 (NH) cm
-1
 
1
H-NMR (CDCl3): 3.76 (2H, t,  J=6.3 Hz, CH2), 4.92 (2H, t, J=6.3Hz. CH2 ), 7.78-7.97 (3H, 
m, 3xAr-H), 8.20 (1H, s, Ar-H), 8.32 (1H, s, Ar-H), 8.53 (1H, dd, J=1.1,6.9 Hz, Ar-H), 8.92 
(1H, d, J=0.6 Hz, Ar-H). 
13
C-NMR (CDCl3): 29.17 (t), 48.72 (t), 119.0 (d), 124.7 (d), 127.5 (s), 128.5 (d), 128.8 (d), 
129.6 (d), 131.9 (d), 132.3 (s), 132.8 (s), 133.7 (d), 135.5 (s),138.1 (s), 139.6 (s), 161.8 (s), 
191.2 (s).  
 
N
1
-(2,3-Dimethyl-isoindolo[2,1-a]quinoxalin-6-yl)-ethane-1,2-diamine 40e 
m.p.174
°
C , Yield 68 %, IR: 3676, 3558 (NH2), 3380 (NH) cm
-1
 
1
H-NMR (CDCl3): 2.50 (6H, s, 2xCH3), 3.76 (2H, t, J=6.4 Hz, CH2), 4.91 (2H, t, J=6.4 Hz, 
CH2), 7.70-7.92 (5H, m, 5xAr-H), 8.51 (1H, dd, J=1,7.8 Hz, Ar-H), 8.92 (1H, dd, J=1, 7.8 
HZ, Ar-H). 
13
C-NMR (CDCl3): 20.2 (q), 20.5 (q), 39.7 (t), 48.7 (t), 124.2 (d), 127.0 (d), 127.1 (d), 127.8 
(s), 128.1 (d), 128.5 (d), 129.6 (s), 130.7 (d), 133.2 (s), 133.3 (d), 134.4 (s), 138.4 (s), 138.9 
(s), 139.7 (s), 141.8 (s). 
 
Synthesis of 5-Bromo-2-isothiocyanato-pyridine 43 
1,1‟Thiocarbonyldiimidazole 42 (0.5g, 89.11 mmol) was dissolved under nitrogen 
atmosphere  in chloroform (5 ml) and stirred until compound was  completely dissolved. 
Then 2-Amino 5-bromo pyridine 41 (0.49g, 2.83 mmol) was added and the reaction was 
stirred at room temperature for 12 hrs under nitrogen atmosphere. The resulting precipitate 
was collected by filtration and the crude was purified by chromatography using 
dichloromethane  as eluent. (8:2. DCM:EA) 
M.p. 130
°
C , Yield 72 %,  IR: 2005 (NCS) , 1091 (Br)  cm
-1
 
1
H-NMR (CDCl3): 7.02 (1H, dd, J=0.5,8.4 Hz, Ar-H), 7.82 (1H, dd, J=2.5,8.4 Hz, Ar-H) 
8.48 (1H, d, J=2.5 Hz, Ar-H). 
13
C-NMR (CDCl3): 118.5 (s) , 120.7 (d) , 141.2 (d) , 143.1 (s), 145.1 (s) , 151.08 (d). 
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Synthesis of substituted 1-(5-Bromo-pyridin-2-yl)-3-[2-(6-imino-6H-isoindolo[2,1-
a]quinoxalin-5-yl)-ethyl]-thiourea 44 a-d and 1-(5-Bromo-pyridin-2-yl)-3-[2-
(isoindolo[2,1-a]quinoxalin-6-ylamino)-ethyl]-thiourea 45 a-d. 
The amine intermediates 39a-d and 40a-d was added to a suspension of 5-Bromo-2-
isothiocyanato-pyridine 43 in a DMF and reaction heated to 100°C for 16 hrs. Reaction 
mixture  was cooled to room temperature and poured in ice water then the resulting 
precipitate was collected by filtration and the crude was purified by chromatography using 
dichloromethane and ethyl acetate as eluent (9:1 DCM:EA) 
 
1-(5-Bromo-pyridin-2-yl)-3-[2-(6-imino-6H-isoindolo[2,1-a]quinoxalin-5-yl)-ethyl]-
thiourea 44a 
M.p. 205
°
C, Yield 15%, IR: 3670 (NH), 3557 (NH), 3367 (NH),  1323 (C=S) cm
-1 
1
H-NMR (DMSO-d6): 3.77 (2H, t, J=5.9 Hz, CH2), 4.80 (2H, t, J=5.9 Hz, CH2), 7.38 (1H, d, 
J=8 Hz, Ar-H), 7.83-8.25 (8H, m, 8xAr-H), 8.42 (1H, d, J=9.5 Hz,  Ar-H), 8.61 (1H, d, J=2.5 
Hz, NH), 8.90 (1H, d, J=8 Hz, NH). 
13
C-NMR (DMSO-d6): 39.7 (t), 48.0 (t), 118.8 (d),121.6 (s), 124.1 (d), 127.1 (s), 127.5 (s), 
127.6 (d), 128.0 (d), 128.6 (d), 128.8 (d), 129.7 (d), 131.1 (d), 131.6 (d), 133.7 (d), 135.5 (s), 
138.5 (s), 140.2 (s), 142.0 (d), 143.5 (s), 143.8 (s), 150.7 (d), 151.3 (s).  
 
 1-(5-Bromo-pyridin-2-yl)-3-[2-(6-imino-3-methoxy-6H-isoindolo[2,1-a]quinoxalin-5-yl)-
ethyl]-thiourea 44b 
M.p. 243
°
C, Yield 10 % , IR:
 
3680 (NH), 3558 (NH), 3408 (NH), 1297 (C=S) cm
-1
  
1
H-NMR (DMSO-d6):  3.95 (3H, s, OCH3) 4.20 (2H, m, CH2), 4.90 (2H, t, J=5Hz,CH2), 
6.77 (1H, d, J=8.6 Hz, Ar-H), 7.01 (1H, d, J=2.7 Hz, Ar-H), 7.35 (1H, dd, J=2,9 Hz,Ar-H), 
7.68-8.10 (6H, m, 6xAr-H), 8.31 (1H d, J=8 Hz, Ar-H), 8.82 (1H, d, J=6 Hz, NH), 10.44 (1H, 
s, NH), 11.22 (1H, t, J=4Hz, NH).   
13
C-NMR (DMSO-d6): 40.2 (t), 43.9 (t), 56.7 (q), 106.2 (d),112.4 (d), 114.7 (d), 122.2 (d), 
124.4 (d), 127.7 (s), 128.8 (d), 130.5 (d), 131.5 (d), 132.4 (d), 133.4 (s), 133.6.(s), 134.3 (d), 
135.1 (s), 142.8 (d), 145.0 (s), 146.0 (s), 152.6 (s),162.0 (s), 162.3 (s), 180.8 (s).  
 
1-(5-Bromo-pyridin-2-yl)-3-[2-(6-imino-3-methyl-6H-isoindolo[2,1-a]quinoxalin-5-yl)-
ethyl]-thiourea 44c 
M.p. 241
°
C, Yield 11%, IR: 3679 (NH), 3570 (NH), 3384 (NH), 1297 (C=S) cm
-1
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1
H-NMR (DMSO-d6): 2,71 (3H, s, CH3), 2.24 (2H, d, J=4.0 Hz, CH2), 4.93 (2H, t, J=4.0Hz, 
CH2), 6.77 (1H, d, J=8 Hz, Ar-H), 7.44 (1H, d, J=4 Hz, Ar-H), 7.62 (1H, t, J=2 Hz, Ar-H), 
7.67 (1H, d, J=2 Hz, Ar-H), 7.85-8.13 (4H, m, 4xAr-H), 8.37 (1H, dd, J=8 Hz, Ar-H), 8.53 
(1H, t, J=2Hz, Ar-H),8,89 (1H, dd, J=2 Hz, Ar-H), 10.47 (1H, s, NH), 11.12 (1H, t, J=6Hz, 
NH). 
13
C-NMR (DMSO-d6): 17.3 (q), 29.7 (t), 77.2 (t), 115.3 (d), 120.1 (d), 124.7 (d), 127.3 (d), 
128.1 (d), 128.3 (d), 130.9 (d), 131.1 (d), 133.6 (d), 133.8 (s), 134.7 (d), 135.9 (s), 140.4 (s), 
140.9 (d), 141.8 (s), 149.3 (s), 154.8 (s), 162.1 (s), 165.1 (s), 170.3 (s), 179.8 (s). 
 
1-(5-Bromo-pyridin-2-yl)-3-[2-(2,3-dichloro-6-imino-6H-isoindolo[2,1-a]quinoxalin-5-
yl)-ethyl]-thiourea 44d 
M.p. 228
°
C, Yield 10 %, IR:
 
3676 (NH), 3567 (NH), 3394 (NH), 1297 (C=S) cm
-1
 
1
H-NMR (DMSO-d6): 4.19 (2H, t, J=8 Hz, CH2), 4.86 (2H, t, J=8 Hz, CH2), 6.77 (1H, d, 
J=8.4 Hz, Ar-H), 7.67-7.75 (2H, m, 2xAr-H), 7,84 (1H, s, Ar-H), 7.85-8,08 (3H, m, 3xAr-H), 
8.36 (3H, m, 3xAr-H),  8.82 (1H, d, J=6 Hz, NH), 10.43 (1H, s, NH), 11.18 (1H, t, J=2Hz, 
NH).
 
13
C-NMR (DMSO-d6): 40.1 (t), 42.9 (t), 111.6 (s), 113.7 (d), 116.3 (d), 117.1 (s), 118.3 (s), 
124.1 (d), 127.6 (d), 127.8 (d), 128.0 (s), 129.0 (d), 130.5 (s), 131.9 (d), 133.2 (s), 133.5 (d), 
136.8 (s), 138.8 (s), 140.7 (d), 145.1 (d), 147.6 (s), 151.1 (s), 161.4 (s), 
 
1-(5-Bromo-pyridin-2-yl)-3-[2-(isoindolo[2,1-a]quinoxalin-6-ylamino)-ethyl]-thiourea 
45a 
M.p. 198
°
C, Yield 10 %, IR:
 
3678 (NH), 3538 (NH), 3403 (NH),1328 (C=S) cm
-1
 
1
H-NMR (DMSO-d6): 4.22 (2H, t, J=5 Hz, CH2), 4.90 (2H, t, J=5 Hz, CH2), 7.76 (1H, d, 
J=9 Hz, Ar-H), 7.67-8.13 (8H, m, 8xAr-H), 8.35 (1H, d, J=7.1 Hz, Ar-H), 8.89 (1H, d, J=7.5 
Hz, Ar-H), 10.42 (1H, s, NH), 11.21 (1H, t, J=5 Hz,NH).  
13
C-NMR (DMSO-d6): 40.3 (t), 42.8 (t), 111.5 (d), 113.8 (d), 113.9 (d), 123.9 (d), 127.3 (d), 
127.9 (d), 128.2 (d), 130.6 (d), 131.4 (d), 132.4 (s), 133.4 (d), 135.4 (s), 135.6 (s), 138.1 (s), 
140.0 (s), 140.7 (d), 143.9 (s), 145.2 (d), 151.6 (s), 161.3 (s), 179.9 (s). 
 
1-(5-Bromo-pyridin-2-yl)-3-[2-(3-methoxy-isoindolo[2,1-a]quinoxalin-6-ylamino)-ethyl]-
thiourea 45b  
M.p. 239
°
C,Yield 16%, IR:
 
3688 (NH), 3584 (NH), 3400 (NH), 1297 (C=S) cm
-1 
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1
H-NMR (DMSO-d6): 4.37 (3H, s, OCH3), 4.63 (2H, m, CH2), 5.34 (2H, t, J=4.7 Hz, CH2), 
7.20 (1H, d, J=8 Hz, Ar-H), 7.58 (1H, d, J=2Hz, Ar-H ), 7.77 (1H, dd, J=2,9 Hz, Ar-H), 8.06-
8.46 (6H, m, 6xAr-H), 8.77 (1H, dd, J=2,2 Hz, Ar-H), 9.25 (1H, dd, J=2,2 Hz, Ar-H), 10.86 
(1H, s, NH), 11.64 (1H, t, J=6Hz, NH).  
13
C-NMR (DMSO-d6): 40.2 (t), 43.9 (t), 56.7 (q), 106.22 (d),112.4 (d), 114.7 (d), 122.2 (d), 
124.4 (d), 127.7 (s), 128.8 (d), 130.5 (d), 131.5 (d), 132.4 (d), 133.4 (s), 133.6.(s), 134.3 (d), 
135.1 (s), 142.8 (d), 145.0 (s), 146.0 (s), 152.6 (s),162.0 (s), 162.3 (s), 180.8 (s).  
 
1-(5-Bromo-pyridin-2-yl)-3-[2-(3-methyl-isoindolo[2,1-a]quinoxalin-6-ylamino)-ethyl]-
thiourea 45c 
M.p. 230
°
C ,Yield 15%, IR: 3757 (NH), 3570 (NH), 3406 (NH),1297 (C=S) cm
-1
 
  
1
H-NMR (DMSO-d6): 2.71 (3H, s, CH3), 4.24 (2H, m, CH2), 4.92 (2H, t, J=5.1 Hz, CH2), 
6.77 (1H, d, J=4 Hz, Ar-H), 7.43 (1H, d, J=4Hz, Ar-H), 7.60-8.13 (7H, m, 7xAr-H), 8.37 
(1H, dd, J=2,8Hz, Ar-H), 8.89 (1H, dd, J=2,2 Hz, Ar-H), 10.47 (1H, s, NH), 11.12 (1H, t, 
J=6Hz, NH). 
13
C-NMR (DMSO-d6): 16.7 (q), 42.7 (t), 59.7 (t), 111.5 (d), 113.7 (d), 123.9 (d), 126.2 (d),  
127.4 (d),131.3 (d), 132.4 (d),133.4 (d), 134.9 (s), 135.4 (s), 138.2 (s), 138.9 (s), 140.6 (d),  
141.3 (s), 142.9 (s), 144.9 (d),145.0 (d), 151.5 (s), 161.3 (s), 170.3 (s), 179.8 (s). 
 
1-(5-Bromo-pyridin-2-yl)-3-[2-(2,3-dichloro-isoindolo[2,1-a]quinoxalin-6-ylamino)-
ethyl]-thiourea 45d 
M.p. 235
°
C, Yield 21%, IR:
 
3671 (NH), 3558 (NH), 3414 (NH), 1211 (C=S) cm
-1
 
1
H-NMR(DMSO-d6): 4.19 (2H, t, J=8 Hz, CH2), 4.86 (2H, t, J = 8 Hz, CH2), 6.77 (1H, d,  
J=8.4 Hz, Ar-H), 7.67-7.75 (2H, m, 2xAr-H), 7,84 (1H, s, Ar-H), 7.85-8,08 (3H, m, 3xAr-H), 
8.36 (3H, m, 3xAr-H),  8.82 (1H, d, J=6 Hz, NH), 10.43 (1H, s, NH), 11.18 (1H, t, J=2Hz, 
NH).   
13
C-NMR (DMSO-d6): 40.1 (t), 42.9 (t), 111.6 (d), 113.8 (d), 121.8 (d), 124.1 (d), 127.6 (d), 
127.8 (d), 128.0 (d), 129.0 (d), 129.4 (s), 130.5 (d), 131.9 (s), 132.0 (s), 133.2 (s), 133.6 (d), 
136.9 (s), 138.8 (s), 140.6 (s), 145.0 (s), 145.1 (s), 147.6 (s), 151.6 (s) 
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EXPERIMETAL DATA 
 
Synthesis of substituted amine 57a-c 
The substituted 4-methylpyridine 56a-c (1 g, 5.79 mmol) were dissolved in acetic acid (4 ml), 
and the reaction mixture was stirred at room temperature for 10 minutes. Then iron powder 
(0.6 g, 35.74 mmol) was added, and the reaction was heated at 90°C for 8 hours. The solvent 
was evaporated under reduced pressure, the crude was diluted with water ,  neutralized using 
a aqueous solution of sodium carbonate and extracted with ethyl acetate The organic layer 
was dried over sodium sulphate, filtered and the solvent evaporated under reduced pressure. 
57a-c was obtained 60-70% yield as brown coloured solid. 
 
2-Chloro-4-methyl-pyridin-3-ylamine 57a 
M.p. 72
°
C , Yield 60%,  IR: 3486, 3395 (NH2) cm
-1
.   
1
HNMR (DMSO-d6): 2.1 (3H, s, CH3), 5.27 (2H, bs, NH2), 7.0 (1H, d, J=4.6, Ar-H), 7.5 
(1H, d, J=4.6 Hz, Ar-H). 
13
C-NMR (DMSO-d6): 17.4 (q), 124.8 (d), 131.4 (d), 134.9 (s), 135.7 (s), 139.4 (s). 
 
6-Chloro-4-methyl-pyridin-3-ylamine 57b 
M.p. 75 
°
C , Yield 65 %,  IR:  3378, 3307 (NH2) cm
-1
. 
1
HNMR (DMSO-d6):  2.07 (3H, s, CH3), 5.7 (2H, bs, NH2), 7.04 (1H, s, Ar-H), 7.67 (1H, s, 
Ar-H). 
13
C-NMR (DMSO-d6): 16.6 (q), 124.1 (d), 133.3 (s), 134.3 (d), 136.4 (s), 143.0 (s). 
 
4-Methyl-pyridin-3-ylamine 57-c 
M.p. 98
°
C , yield- 80% IR: 3390, 3320 (NH2) cm
-1
. 
 
1
HNMR(DMSO-d6): 5.06 (3H, s, CH3), 5.07 (2H, s, NH2 ), 6.90 (1H, d, J=4.3 Hz, Ar-H), 
7.67 (1H, d, J=4.5 Hz, Ar-H), 7.91 (1H, s, Ar-H). 
13
C-NMR (DMSO-d6): 16.5 (q), 124.6 (d), 128.3 (s), 135.8 (d), 137.3 (d), 143.2 (s). 
 
Synthesis of substituted (2-Chloro-4-methyl-pyridin-3-yl)-(2-nitro-phenyl)-amine 59a-c 
The amino compounds 57a-c (0.1g, 0.7 mmol) were dissolved in DMF (3 ml) and stirred at 
room temperature for 10 minutes, the reaction mixture was cooled at 0°C, and sodium 
hydride (0.05g, 1.4 mmol) was added. The reaction mixture was warmed to room temperature 
and stirred for 2 hours 1-fluoro-2-Nitrobenzene 58 (0.07g, 0.70 mmol) was added, and the  
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reaction mixture was stirred for additional 6 hours at room temperature. The reaction mixture 
was quenched with saturated ammonium chloride solution, diluted with water, and extracted 
with ethyl acetate. The organic layer was collected, dried over sodium sulphate and 
concentrated under reduced pressure. The crude was purified by chromatography coloumn 
using dichloromethane and ethyl acetate as eluents (6:4 DCM:EA). The amino nitrobenzene 
intermediates 59a-c were obtained as a white solids. 
  
(2-Chloro-4-methyl-pyridin-3-yl)-(2-nitro-phenyl)-amine 59a 
M.p. 96
°
C , Yield 74%,  IR: 3341 (NH), 1495 (NO2) cm
-1
. 
1
HNMR(DMSO-d6): 2.2 (3H, s, CH3), 6.33 (1H, dd, J=0.8, 8.5 Hz, Ar-H), 6.87 (1H ,td, J=1, 
10.1 Hz, Ar-H), 7.46 (1H, m, Ar-H), 8.17 (1H, dd, J=1.4, 8.5 Hz, Ar-H), 8.3 (1H, d, J=4.8 
Hz, Ar-H), 9.38 (1H, s, NH). 
13
C-NMR (DMSO-d6): 17.7 (q), 115.2 (d), 117.5 (d), 125.6 (d), 126.2 (d), 132.0 (s), 132.3 
(s), 136.5 (d), 142.1 (s), 147.4 (d), 150.0 (s), 150.1 (s). 
 
(6-Chloro-4-methyl-pyridin-3-yl)-(2-nitro-phenyl)-amine 59b 
M.p. 115
°
C , Yield 70%,  IR: 3345 (NH), 1497 (NO2) cm
-1
. 
1
HNMR(DMSO-d6): 2.19 (3H, s, CH3), 6.63 (1H, dd, J=0.9, 8.5 Hz,Ar-H), 6.88 (1H, m, Ar-
H), 7.51 (2H, m, 2xAr-H), 8.14 (1H, dd, J=1.4, 8.5 Hz, Ar-H), 8.29 (1H, s, Ar-H), 9.28 (1H, 
s, NH). 
13
C-NMR (DMSO-d6): 16.9 (q), 116.1 (d), 117.8 (d), 125.6 (d), 126.2 (d), 132.9 (s), 134.6 
(s), 136.3 (d), 142.5 (s), 147.3 (s), 148.0 (d), 148.4 (s). 
 
(4-Methyl-pyridin-3-yl)-(2-nitro-phenyl)-amine 59c 
M.p. 109
°
C , Yield 78%, IR: 3347 (NH), 1506 (NO2) cm
-1
. 
1
HNMR(DMSO-d6): 2.20 (3H, s, CH3), 6.57 (1H, d, J=8.6 Hz, Ar-H), 6.85 (1H, t, J=7.1 Hz, 
Ar-H), 7.40-7.51 (2H, m, 2xAr-H), 8.15 (1H, d, J=8.3 Hz, Ar-H), 8.40-8.44 (2H, m, 2xAr-H), 
9.34 (1H, s, NH). 
13
C-NMR (DMSO-d6): 16.8 (q), 115.8 (d), 117.4 (d), 125.7 (d), 126.2 (d), 132.5 (s), 134.6 
(s), 136.3 (d), 143.0 (s), 144.2 (s), 147.3 (d), 148.3 (d). 
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Synthesis of substituted 3-[2-Chloro-3-(2-nitro-phenylamino)-pyridin-4-yl]-2-oxo-
propionic acid ethyl ester 61a-c 
To a mixture diethyl ether (5 ml) and ethanol (1ml), potassium tert-butoxide (0.08g, 0.7 
mmol) was added, the mixture was stirred for 5 minutes at room temperature, then diethyl 
oxalate 60 was added (0.05 ml, 0.3mmol) and the resulting reaction mixture was stirred for 
30 minutes at room temperature. Then amino nitrobenzene intermediates 59a-c (0.1g, 0.3 
mmol) were added and the reaction was refluxed for 6 hours, after which it was cooled at 
room temperature. The solvent was evaporated under reduced pressure and the crude was 
acidified with acetic acid to pH 4 and a precipitation of solid was observed. The solid was 
filtered and purified by chromatography coloumn using dichloromethane and ethyl acetate as 
eluents (9:1 DCM:EA). The  acrylic acid ethyl ester intermediates 61a-c were obtained as 
pale yellow solids. 
 
3-[2-Chloro-3-(2-nitro-phenylamino)-pyridin-4-yl]-2-oxo-propionic acid ethyl ester 61a 
M.p. 154
°
C , Yield 50 %,  IR: 3415 (NH), 1653 (C=O), 1470 (NO2) cm
-1
. 
1
HNMR(DMSO-d6): 1.12 (3H, t,  J=7 Hz, CH3), 4.15 (2H, q,  J=7.1 Hz , CH2), 6.32 (2H, m, 
CH, Ar-H), 6.88 (1H, td,  J=1, 4.7 Hz, Ar-H) , 7.48 (td, 1H, J=7, 7.1 Hz, Ar-H), 8.19 (2H, m, 
2xAr-H), 8.40 (1H, d,  J=5.2 Hz, Ar-H), 9.40 (1H, s,  NH), 10.83 (s, 1H, OH). 
13
C-NMR (DMSO-d6): 13.7 (q), 61.8 (t), 101.5 (d), 115.9 (d), 117.8 (d), 122.8 (d), 126.1 
(d), 129.8 (s), 132.5 (s), 136.5 (d), 142.4 (s), 144.0 (s), 146.6 (s), 147.6 (d), 150.7 (s), 163.4 
(s). 
 
3-[2-Chloro-5-(2-nitro-phenylamino)-pyridin-4-yl]-2-oxo-propionic acid ethyl ester 61b 
M.p. 158
°
C , Yield 50 %, IR: 3424 (NH), 1720 (C=O), 1490 (NO2) cm
-1
. 
1
HNMR(DMSO-d6): 1.12 (3H, t, J=7 Hz, CH3), 4.16 (2H, q, J=7.1 Hz, CH2), 6.27 (1H, s, 
CH), 6.61 (1H, d, J=8 Hz, Ar-H), 6.75 (1H , t, J=8 Hz, Ar-H), 7.42-7.50 (1H, m, Ar-H), 8.12-
8.20 (2H, m, 2xAr-H), 8.36 (1H, d, J=6 Hz, Ar-H), 9.32 (1H, s, NH), 10.91 (1H, s, OH) 
13
C-NMR (DMSO-d6): 13.6 (q), 16.4 (t), 109.6 (d), 115.9 (d), 125.6 (d), 130.1 (d), 130.9 
(d), 131.2 (s), 133.1 (s), 133.6 (s), 134.6 (d), 135.1 (d), 135.4 (s), 140.8 (s), 145.9 (s),      
159.5 (s). 
 
3-[3-(2-Nitro-phenylamino)-pyridin-4-yl]-2-oxo-propionic acid ethyl ester 61c  
M.p. 92
°
C , Yield 52%,  IR: 3423 (NH), 1613 (C=O) ,1509 (NO2) cm
-1
. 
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1
HNMR(DMSO-d6): 1.16 (3H, t, J=8 Hz, CH3), 4.15 (2H, q, J=8.1 Hz, CH2), 6.32 (2H, m, 
2xAr-H), 6.88 (1H, t, J=7.5 Hz, Ar-H), 7.46 (1H, t, J=7.3 Hz, Ar-H), 8.20 (2H, m, 2xAr-H), 
8.40 (1H, t, J=2.2 Hz, Ar-H),  9.38 (1H, s, NH), 10.80 (1H, s, OH). 
13
C-NMR (DMSO-d6): 13.7 (q), 61.8 (t), 101.5 (d), 115.8 (d), 117.8 (d), 122.8 (d), 126.1 
(d), 129.8 (d), 132.4 (s), 136.5 (d), 142.4 (s), 144.1 (s), 146.5 (s), 147.7 (d), 150.7 (s), 163.3 
(s).  
 
Synthesis of substituted 1-(2-nitro-phenyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid 
ethyl ester 62 a-c 
The acrylic acid ethyl ester intermediates 61a-c (0.5g, 2.59 mmol) were dissolved in acetic 
acid (10 ml) and refluxed for 2 hours . The reaction mixture was poured into ice and water 
(150 ml) and the resulting precipitate was collected by filtration and recrystallized from 
ethanol. The substituted Chloro-1-(2-nitro-phenyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic 
acid ethyl ester 62a-c were obtained as white solid. 
 
7-Chloro-1-(2-nitro-phenyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid ethyl ester 62 a 
M.p. 131
°
C , Yield 65 %,  IR:  1721 (C=O), 1530 (NO2) cm
-1
. 
1
HNMR(DMSO-d6): 1.12 (3H, t, J=7 Hz, CH3), 4.15 (2H, q, J=7.1 Hz, CH2), 7.65 (1H, s, 
Ar-H), 7.85 (4H, m, 4xAr-H), 8.14 (1H, d, J=5.06 Hz, Ar-H), 8.30 (1H, d, J=5.76 Hz, Ar-H). 
13
C-NMR (DMSO-d6): 13.6 (q), 61.3 (t), 110.7 (d), 117.1 (d), 124.8 (d), 131.1(d),131.2 (s), 
131.4 (s), 132.6 (d), 132.9 (s), 133.7 (s), 133.9 (s), 134.1 (d), 138.9 (d), 146.9 (s), 159.3 (s). 
 
5-Chloro-1-(2-nitro-phenyl)-1H-pyrrolo[2,3-c]pyridine-3-carboxylic acid ethyl ester 62b 
M.p. 122
°
C , Yield 63%,  IR: 1717  (C=O), 1532 (NO2) cm
-1
. 
1
HNMR(DMSO-d6): 1.13 (3H, t, J=9.5 Hz, CH3), 4.16 (2H, q, J=10 Hz, CH2), 7.53 (1H, s, 
Ar-H), 7.81-8.04 (4H, m, 4xAr-H), 8.30 (1H, s, Ar-H), 8.33 (1H, dd, J=2.3,7.5 Hz, Ar-H). 
13
C-NMR (DMSO-d6): 13.6 (q), 61.3 (t), 110.7 (d), 117.1 (d), 124.8 (d), 131.1(d),131.2 
(s),131.4 (s), 132.6 (d), 132.9 (s), 133.7 (s), 133.9 (s), 134.1 (d), 138.9 (d), 146.9 (s), 159.3 
(s). 
 
1-(2-Nitro-phenyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid ethyl ester 62c 
M.p. 137
°
C , Yield  60%,  IR: 1725 (C=O) , 1530 (NO2) cm
-1
. 
1
H-NMR (DMSO-d6): 1.12 (3H, t, J=6.9 Hz, CH3), 4.15 (2H, q, J=6.7 Hz, CH2), 7.65-7.80 
(6H, m, 6xAr-H), 8.14 (1H, d, J=5 Hz, Ar-H), 8.30 (1H, d, J=7 Hz, Ar-H). 
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13
C-NMR (DMSO-d6): 13.6 (q), 61.3 (t), 110.7 (d), 117.1 (d), 124.8 (d), 131.14 (d), 131.17 
(d), 131.4 (s), 132.6 (d), 132.9 (s), 133.7 (s), 133.9 (s), 134.1 (d), 138.9 (d), 146.9 (s), 159.4 
(s). 
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